ACM derived from OGJ patients with early-stage tumours had significantly increased levels of pro-inflammatory TNF-α compared with ACM derived from OGJ patients with late-stage tumours (early-stage: 2,730 ± 1,412 vs. late-stage: 806.1 ± 131.8 pg/gram p = 0.05) (Figure S1). The gene discussed is TNF; the disease is neoplasm.